Drugs / BGB-58067
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07485049 | May 2026 → Nov 2027 expected | glioblastoma | Nader Sanai | Recruiting | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT07712640 | Jul 2026 → Jul 2027 expected | — | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1 | NCT07590102 | Jun → Oct 2026 expected | — | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1 | NCT06589596 | Jan 2025 → Sep 2027 expected | neoplasm | BeOne Medicines | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGB-58067 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07485049 ↗ |
| Action | Inhibit | “PRMT5 Inhibitor BGB-58067” NCT06589596 ↗ |
| Route | Oral | “Administered orally” NCT07712640 ↗ |
| Target | PRMT5 | “PRMT5 Inhibitor” NCT07485049 ↗ |